Skip to main content

Advertisement

SpringerLink
Log in

When drug companies select what they want to publish patients are denied relevant therapeutic information

  • CE - Cochrane's Corner
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Goodin DS, Frohman EM, Garmany GP Jr et al (2002) Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169–178

    PubMed  CAS  Google Scholar 

  2. Multiple Sclerosis Therapy Consensus Group (2004) Escalating immunotherapies of multiple sclerosis. J Neurol 251:1329–1339

    Article  Google Scholar 

  3. Freedman MS, Blumhardt LD, Brochet B, Comi G, Noseworthy JH, Sandberg-Wollheim M, et al. Paris Workshop Group (2002) International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 8:19–23

    Google Scholar 

  4. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D’Amico R, Rice GP (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361:545–552 Cochrane Review

    Article  PubMed  CAS  Google Scholar 

  5. Montori VM, Guyatt GH (2001) Intention-to-treat principle. CMAJ 165:1339–1341

    PubMed  CAS  Google Scholar 

  6. Biogen. Summary basis of approval: FDA official document for license of interferon beta-1a (Avonex). http://www.fda.gov/cber/products/ifnbbio051796.htm. Accessed on 11 May 2003

  7. Burke K (2002) NICE accuses drug companies of withholding data. BMJ 324:320

    Article  Google Scholar 

  8. DeAngelis CD, Fontanarosa PB (2008) Impugning the integrity of medical science: the adverse effects of industry influence. JAMA 299:1833–1835

    Article  PubMed  CAS  Google Scholar 

  9. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    PubMed  CAS  Google Scholar 

  10. Weinshenker BG, Bass B, Rice GPA et al (1989) The natural history of multiple sclerosis: a geographically based study: I: clinical course and disability. Brain 112:133–146

    Article  PubMed  Google Scholar 

  11. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294

    Article  PubMed  CAS  Google Scholar 

  12. Goodkin DE, Cookfair D, Wende K et al (1992) Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke expanded disability status scale (EDSS). Neurology 42:859–863

    PubMed  CAS  Google Scholar 

  13. Beer MH, Porter RS, Jones TV (Eds) (2006)The Merck manual of diagnosis and therapy, 18th edn

  14. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D’Amico R, Rice GP (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361:545–552

    Article  PubMed  CAS  Google Scholar 

  15. Sackett DL, Richardson WS, Rosenberg W, Haynes RB (1997) Evidence-based medicine. How to practice and teach EBM. Churchill Livingstone, London

    Google Scholar 

  16. Vandenbroucke JP (1999) Roaming through the methodology. XIV. The premature ending of a randomized trial. Ned Tijdschr Geneeskd 143:1305–1308

    PubMed  CAS  Google Scholar 

  17. Gensini GF, Conti AA (2004) The evaluation of the results of clinical trials: surrogate end points and composite end points. Minerva Med 95:71–75

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

    Graziella Filippini

  2. Italian Cochrane Centre, Mario Negri Institute for Pharmacological Research, Via Eritrea 62, 20157, Milan, Italy

    Lorenzo Moja & Alessandro Liberati

  3. Department of Critical Care Medicine and Surgery, University of Florence and Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

    Gian Franco Gensini

  4. DAI Cardiologico e dei Vasi, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

    Roberto Gusinu

  5. Department of Critical Care Medicine and Surgery, University of Florence and Don Carlo Gnocchi Foundation IRCCS, Florence, Italy

    Andrea A. Conti

Authors
  1. Graziella Filippini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorenzo Moja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Liberati
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gian Franco Gensini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roberto Gusinu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea A. Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lorenzo Moja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filippini, G., Moja, L., Liberati, A. et al. When drug companies select what they want to publish patients are denied relevant therapeutic information. Intern Emerg Med 3, 255–257 (2008). https://doi.org/10.1007/s11739-008-0174-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-008-0174-7

Search

Navigation